By fostering a deeper understanding of Ga68 PSMA PET-CT’s pivotal role in optimizing clinical outcomes for patients with prostate cancer, we aim to pave the way for more personalized and effective approaches to diagnosis and management. This evidence concerns the gene FOLH1 and prostate carcinoma.